Near Transform-Limited Quantum Dot Linewidths in a Broadband Photonic Crystal Waveguide

Planar nanophotonic structures enable broadband, near-unity coupling of emission from quantum dots embeddedwithin, thereby realizing ideal singe-photon sources. The efficiency and coherence of the single-photon source islimited by charge noise, which results in the broadening of the emission spectrum. We report suppression of the noiseby fabricating photonic crystal waveguides in a gallium arsenide membrane containing quantum dots embedded in ap-i-ndiode. Local electrical contacts in the vicinity of the waveguides minimize the leakage current and allow fastelectrical control (≈4 MHz bandwidth) of the quantum dot resonances. Resonant linewidth measurements of 79 quan-tum dots coupled to the photonic crystal waveguides exhibit near transform-limited emission over a 6 nm wide range ofemission wavelengths. Importantly, the local electrical contacts allow independent tuning of multiple quantum dots onthe same chip, which together with the transform-limited emission are key components in realizing multiemitter-basedquantum information processing

On-chip deterministic operation of quantum dots in dual-mode waveguides for a plug-and-play single-photon source

A deterministic source of coherent single photons is an enabling device of quantum-information processing for quantum simulators, and ultimately a full-fledged quantum internet. Quantum dots (QDs) in nanophotonic structures have been employed as excellent sources of single photons, and planar waveguides are well suited for scaling up to multiple photons and emitters exploring near-unity photon-emitter coupling and advanced active on-chip functionalities. An ideal single-photon source requires suppressing noise and decoherence, which notably has been demonstrated in electrically-contacted heterostructures. It remains a challenge to implement deterministic resonant excitation of the QD required for generating coherent single photons, since residual light from the excitation laser should be suppressed without compromising source efficiency and scalability. Here, we present the design and realization of a novel planar nanophotonic device that enables deterministic pulsed resonant excitation of QDs through the waveguide. Through nanostructure engineering, the excitation light and collected photons are guided in two orthogonal waveguide modes enabling deterministic operation. We demonstrate a coherent single-photon source that simultaneously achieves high-purity ($g^{(2)}(0)$ = 0.020 $\pm$ 0.005), high-indistinguishability ($V$ = 96 $\pm$ 2 %), and $>$80 % coupling efficiency into the waveguide. The novel `plug-and-play' coherent single-photon source could be operated unmanned for several days and will find immediate applications, e.g., for constructing heralded multi-photon entanglement sources for photonic quantum computing or sensing.Comment: 12 pages, 10 figure

Near Transform-Limited Quantum Dot Linewidths in a Broadband Photonic Crystal Waveguide

Planar nanophotonic structures enable broadband, near-unity coupling of emission from quantum dots embeddedwithin, thereby realizing ideal singe-photon sources. The efficiency and coherence of the single-photon source islimited by charge noise, which results in the broadening of the emission spectrum. We report suppression of the noiseby fabricating photonic crystal waveguides in a gallium arsenide membrane containing quantum dots embedded in ap-i-ndiode. Local electrical contacts in the vicinity of the waveguides minimize the leakage current and allow fastelectrical control (≈4 MHz bandwidth) of the quantum dot resonances. Resonant linewidth measurements of 79 quan-tum dots coupled to the photonic crystal waveguides exhibit near transform-limited emission over a 6 nm wide range ofemission wavelengths. Importantly, the local electrical contacts allow independent tuning of multiple quantum dots onthe same chip, which together with the transform-limited emission are key components in realizing multiemitter-basedquantum information processing

Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies.

Oligopeptidic derivatives of anthracyclines unable to penetrate cells were prepared and screened for their stability in human blood and their reactivation by peptidases secreted by cancer cells. N-beta-alanyl-L-leucyl-L-alanyl-L-leucyl-doxorubicin was selected as a new candidate prodrug. The NH2-terminal beta-alanine allows a very good blood stability. A two-step activation by peptidases found in conditioned media of cancer cells ultimately yields N-L-leucyl-doxorubicin. In vitro, when MCF-7/6 cancer cells are exposed to the prodrug, they accumulate about 14 times more doxorubicin than MRC-5 normal fibroblasts, whereas when exposed to doxorubicin the uptake is slightly higher in fibroblasts than in MCF-7/6 cells. This increased specificity of the prodrug over doxorubicin was confirmed in cytotoxicity assays using the same cell types. In vivo, the prodrug proved about nine times less toxic than doxorubicin in the normal mouse and also much more efficient in two different experimental chemotherapy models of human breast tumors

N-Succinyl-(beta-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity.

Intravenous administration of N-(beta-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin (4) induces an acute toxic reaction, killing animals in a few minutes. This results from its positive charge at physiological pH combined with its propensity to form large aggregates in aqueous solutions. Negatively charged N-capped versions of 4 such as the succinyl derivative 5 can be administered by the iv route at more than 10 times the LD(50) of doxorubicin without inducing the acute toxic reaction, and they are active in vivo

CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.

The search for cancer therapies that are more selective for tumor cells and spare normal sensitive cells has been very active for at least 20 years. The extracellularly tumor-activated peptidic prodrug of doxorubicin (Dox) CPI-0004Na (N-succinyl-beta-alanyl-L-leucyl-L-alanyl-L-leucyl-Dox) is potentially such a treatment. Here, we report the results of lethality studies performed with this compound in the mouse, showing that it is up to 4.6 times less toxic than Dox.HCl by the i.v. route and up to 16.2 times after i.p. administration. Pharmacokinetics and tissue distribution data indicate that this reduced toxicity is attributable to a lower uptake of Dox in normal tissues after treatment with CPI-0004Na than after the administration of an equimolar dose of Dox.HCl. For example, heart exposure to Dox is reduced >10-fold. Because of this reduced toxicity, higher doses of CPI-0004Na than of the parent drug could be used to treat nude mice bearing s.c. human breast (MCF-7/6) and colon (LS-174-T and CXF-280/10) tumors. In all three models, the prodrug showed a much improved efficacy as compared with Dox.HCl. Particularly, LS-174-T tumors that do not respond to Dox were inhibited by 68% after treatment with CPI-0004Na. Tissue distribution studies performed with MCF-7/6 tumor-bearing nude mice and comparing CPI-0004Na and Dox.HCl confirmed that the improved activity of the prodrug is actually the result of selective generation and uptake of Dox at the tumor site. Dox levels in tumor tissue were 2-fold higher after treatment with CPI-0004Na than after treatment with an equimolar dose of Dox.HCl, whereas normal tissue levels were reduced 1.4-29-fold